Non-Hodgkin’s

Optimizing CAR-T cell activity to treat Non-Hodgkin’s lymphoma and leukemia

Amplify and train CAR-T cells to deliver more potent anti-cancer activity—ultimately, enabling the cure of previously fatal lymphomas and leukemias.

Albert Einstein College of Medicine
New York, United States
Dr. Harris Goldstein
Lead Researcher

$0

of $200,000 goal

Flexible

info

Flexible Goal

This research will receive all of the funds raised regardless of whether it meets its overall funding goal.

Champion this research!

Champions take a more active role in supporting a research project. They help drive awareness and donations by promoting the project with their network and/or matching donations.

Donate

Kernls helps fund medical science

Kernls is a platform where you can access and donate directly to scientific research projects from top scientists at world-renown institutions. Read our FAQ

Project Start-Up
Help raise $200,000 to get this project launched!

Project Summary

Lymphoma impacts the lymph system, which functions within the immune system—meaning the place that fights infection and disease in your body is under attack by this type of cancer. While the infected cells begin in places such as lymph nodes, the spleen, and digestive tract, it is a rapidly progressive disease that can aggressively grow and spread.

We want to train cells to deliver more potent anti-cancer activity. We will work with highly immunodeficient mice to create a model to evaluate our CAR-T cell therapy approach. It is our near-term aim to advance into clinical trial design and implementation to treat relapsed lymphoma and leukemia. To get there, our year-long Phase 1 will focus on perfecting concept, experimental protocol, and initial testing.

timeProject Length1 year
targetGoalLaunch preliminary research to create the most effective strategy for CAR-T cells to attack malignant cells
bottleResearch TypeExploratory

Why This Research is Important

81,560

people are diagnosed with Non-Hodgkin’s lymphoma in the U.S annually.

23,100

patients die from Non-Hodgkin’s lymphoma every year in the US.

By converting highly functional cytotoxic T cells into CAR-T cells, we hypothesize that we could generate CAR-T cells with more potent anti-cancer activity and prolong their lifespan in patients.

To visualize, this is like forming an army recruited from Olympic biathlon teams with previous military experience—and having high expectations that they will be more effective soldiers than, say, random individuals with no previous training (a good comparison for how CAR-T cells currently work).

What Funding Helps Achieve

PROJECT START-UP 2021

Build the team, research plan, and preliminary testing strategy to begin defining and driving a powerful protocol for CAR-T cell development.

Facilities & admin (2.5%), Personnel (50%), Equipment (10%), Materials and supplied (25%), Animal models (10%), Drugs (2.5%), Publication (1.5%) = $200,000 (USD)

Research Team

Harris Goldstein, MD

Lead Researcher

H-Index

 

H-Index reflects how often a researcher's published work is cited by others. It's used as an indication of their impact and productivity.

: 27

Dr. Goldstein is a leading expert in microbiology, immunology, and autoimmune diseases with a specific focus on cancer and HIV research and genetic programming of immune responses, among other scientific areas.

Albert Einstein College of Medicine

New York, United States

Einstein research teams have contributed to the world’s knowledge base in life-saving ways, including leading the largest early-stage breast cancer clinical trial in history. We also discovered a compound that makes cancer cells self-destruct while sparing healthy cells and drove the clinical trial into the first promising drug against COVID-19, among other notable breakthroughs.

The research enterprise is growing quickly with $197.3 million in NIH funding earned in 2020.